CAPTRUST Financial Advisors
CLDX icon

CAPTRUST Financial Advisors’s Celldex Therapeutics CLDX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-618
Closed -$17K – 2417
2022
Q2 		$17K Buy
618
+574
+1,305% +$16.7K ﹤0.01% 3450
2022
Q1 		$1K Sell
44
-72
-62% -$2.3K ﹤0.01% 4666
2021
Q4 		$4K Sell
116
-1,506
-93% -$65.6K ﹤0.01% 4166
2021
Q3 		$88K Buy
+1,622
New +$76.1K ﹤0.01% 2172

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CAPTRUST Financial Advisors's CLDX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 618 shares — an estimated $17K sold.

CAPTRUST Financial Advisors first reported a position in CLDX in Q3 2021 and held it in 4 quarters. The position peaked at $88K in Q3 2021. 159 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 618 Celldex Therapeutics shares in Q3 2022, an estimated $17K.
  • CAPTRUST Financial Advisors first reported a position in Celldex Therapeutics in Q3 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Celldex Therapeutics position peaked at $88K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.